Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 25, 2025-

#Advancements in Immuno-Oncology Updated Phase 1 Data for Botensilimab and Balstilimab in Hepatocellular Carcinoma

:' The landscape of hepatocellular carcinoma (HCC) treatment continues to evolve with the ongoing developments in immuno-oncology. Agenus Inc. has made significant strides with its dual therapy of botensilimab (BOT) and balstilimab (BAL), which demonstrates promise in pretreated, difficult-to-treat liver cancer patients. This article reviews the latest findings from the Phase 1 study presented at the American Association for Cancer Research (AAC…